Now showing items 9-10 of 10

  • Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival 

    Poli, Aurélie; Wang, Jian; Domingues, Olivia; Planagumà, Jesús; Yan, Tao; Rygh, Cecilie Brekke; Skaftnesmo, Kai Ove; Thorsen, Frits Alan; McCormack, Emmet; Hentges, François; Pedersen, Paal-Henning; Zimmer, Jacques; Enger, Per Øyvind; Chekenya, Martha (Impact Journals, 2013-09-09)
    Glioblastoma (GBM) is the most malignant brain tumor where patients’ survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet ...
    Journal article
  • Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma 

    Wang, Jian; Svendsen, Agnete; Kmiecik, Justyna; Immervoll, Heike; Skaftnesmo, Kai Ove; Planagumà, Jesús; Reed, Rolf K.; Bjerkvig, Rolf; Miletic, Hrvoje; Enger, Per Øyvind; Rygh, Cecilie Brekke; Chekenya, Martha (PLoS Computational Biology, 2011-07-29)
    Aberrant expression of the progenitor marker Neuron-glia 2 (NG2/CSPG4) or melanoma proteoglycan on cancer cells and angiogenic vasculature is associated with an aggressive disease course in several malignancies including ...
    Peer reviewedJournal article